3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
10
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Pain, Postoperative
3
Neurotoxicity Syndromes
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Brain Neoplasms
3
Recurrence
2
Ovarian Neoplasms
2
Hemorrhage
2
Chronic Pain
2
Agnosia
2
Vulvodynia
1
Uterine Cervical Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Seizures
1
Radiodermatitis
1
Radiation Injuries
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Complications
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Parathyroid Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Interventions
Paclitaxel
25
Doxorubicin
15
Carboplatin
14
pembrolizumab
10
Cisplatin
8
Radiotherapy
6
Docetaxel
5
Chemotherapy, Adjuvant
5
Taxes
4
Filgrastim
4
Brachytherapy
4
lenvatinib
3
Observation
3
trastuzumab deruxtecan
2
selinexor
2
olaparib
2
durvalumab
2
Tamoxifen
2
Specimen Handling
2
Ifosfamide
2
Drug Therapy
2
sintilimab
1
sacituzumab govitecan
1
pertuzumab
1
nanocis
1
liposomal doxorubicin
1
ixabepilone
1
gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
dostarlimab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Endometrial Neoplasms
×
Sodium Chloride
×
Clear all
NCT04237090
2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3
Completed
27 enrolled